For DYNE-251 too, the company plans to complete enrollment in the registrational expansion cohort of the phase I/II DELIVER study in 2025 with a goal to submit applications for accelerated approvals in 2026 The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page . CRDL stock price forecasts from top research houses imply an annual potential upside of 15%, driven by pipeline expansion and favorable market conditions.